Pregnancy

Raltegravir has not been studied in pregnant women and is classified by the US FDA as a pregnancy category C drug. This means that animal studies have shown an adverse effect on the foetus and there are no adequate and well-controlled studies in humans, but that potential benefits may warrant use of the drug in pregnant women despite potential risks.

It is not known whether raltegravir passes into breast milk and what effect it may have on a nursing baby. If a woman becomes pregnant while on raltegravir, she should consult her healthcare provider about the drug's use during pregnancy.

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.